HCV: APASL issues HBV guidance for patients receiving DAA therapy

  • Kanda T & al.
  • Hepatol Int
  • 20.09.2019

  • von Yael Waknine
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • The Asian Pacific Association for the Study of the Liver (APASL) has issued new guidelines for patients with current/prior HBV coinfection receiving HCV direct-acting antivirals (DAAs).

Supporting data

  • Experts reviewed data from 14 studies on HBV DNA reappearance and clinical reactivation among patients receiving DAA therapy.
  • Across 8 studies, viral DNA/clinical reactivation occurred in 41.4% (67/162) of patients positive for HBV surface antigen (HBsAg+) over a mean of 3 months posttreatment.
  • Among patients positive for anti-HBV core (anti-HBc) and/or anti-HBV surface (anti-HBs) antibodies at baseline, the 3-month rate was 0.91% (12/1317).

Recommendations for patients coinfected with HBV and HCV

  • HBsAg should be evaluated at baseline in HBV-endemic areas.
  • HBsAg+ patients with advanced fibrosis, cirrhosis, or prior hepatocellular carcinoma should receive preemptive treatment with nucleos(t)ide analogs (NAs).
  • In the absence of these conditions, HBsAg+ patients should receive preemptive NAs or close monitoring during treatment and for 24 weeks thereafter.
  • HBsAg-negative patients with anti-HBc/HBs antibodies should be tested for HCV RNA, HBsAg, and HBV DNA if liver function tests are abnormal during or after DAA treatment.
    • NAs should be used to treat HBV reactivation.
  • The above provides only an overview, and clinicians should consult the complete guidelines for details.
  • Funding: None.